BRIEF published on 07/22/2025 at 07:05, 8 months 4 days ago Sartorius annonce une forte croissance au premier semestre 2025 Sartorius AG Sciences De La Vie Augmentation De L'EBITDA Premier Semestre 2025 Croissance Des Bioprocédés
BRIEF published on 07/22/2025 at 07:05, 8 months 4 days ago Sartorius Reports Strong Growth in First Half of 2025 Life Sciences Sartorius AG EBITDA Increase First Half 2025 Bioprocess Growth
PRESS RELEASE published on 07/22/2025 at 07:00, 8 months 4 days ago Sartorius continues growth course; earnings rise at a significantly overproportionate rate Sartorius AG reports continued growth with significant increase in earnings for the first half of 2025. Group's sales revenue up 6.1%. CEO confirms guidance for the full year 2025 Sales Revenue Growth Earnings Sartorius AG Guidance
BRIEF published on 07/01/2025 at 17:35, 8 months 25 days ago Sartorius Finalizes Acquisition of MatTek Acquisition Sartorius Drug Development MatTek Cell Technology
BRIEF published on 07/01/2025 at 17:35, 8 months 25 days ago Sartorius finalise l'acquisition de MatTek Acquisition Sartorius Développement De Médicaments MatTek Technologie Cellulaire
PRESS RELEASE published on 07/01/2025 at 17:30, 8 months 25 days ago Sartorius completes acquisition of MatTek Sartorius completes acquisition of MatTek from BICO Group AB, expanding its cell technology portfolio and creating synergies with existing solutions for drug development Acquisition Sartorius Drug Development MatTek Cell Technology
BRIEF published on 05/02/2025 at 09:27, 10 months 24 days ago Sartorius prolonge le mandat d'Alexandra Gatzemeyer au conseil d'administration Sartorius AG Industrie Biopharmaceutique Conseil Exécutif Alexandra Gatzemeyer Produits De Laboratoire
BRIEF published on 05/02/2025 at 09:27, 10 months 24 days ago Sartorius Extends Executive Board Tenure for Alexandra Gatzemeyer Executive Board Sartorius AG Biopharmaceutical Industry Alexandra Gatzemeyer Lab Products
PRESS RELEASE published on 05/02/2025 at 09:22, 10 months 24 days ago Sartorius Supervisory Board extends appointment of board member Alexandra Gatzemeyer Sartorius AG extends Dr. Alexandra Gatzemeyer's Executive Board appointment until 2031, responsible for Lab Products & Services Division Executive Board Sartorius AG Appointment Extension Alexandra Gatzemeyer Lab Products & Services Division
BRIEF published on 04/16/2025 at 07:04, 11 months 10 days ago Sartorius annonce un bon début de premier trimestre 2025 Croissance Des Ventes Sartorius AG Marge D'EBITDA Premier Trimestre 2025 Solutions De Bioprocédés
Published on 03/26/2026 at 21:00, 1 hour ago Worksport Reports Record FY 2025 Results, Issues $35M–$42M 2026 Revenue Guidance; Targets Initial Cash Flow Positivity
Published on 03/26/2026 at 21:00, 1 hour ago Rocky Shore Closes Acquisition of Additional Mining Claims
Published on 03/26/2026 at 16:20, 5 hours 40 minutes ago ACCESS Newswire Upgrades the ACCESS Platform to Include Social Monitoring to Track Brand Conversations Across Major Social Platforms
Published on 03/26/2026 at 13:00, 9 hours ago Prospect Ridge Strengthens Technical Team with Appointment of Phil Smerchanski as Senior Technical Advisor
Published on 03/26/2026 at 20:48, 1 hour 12 minutes ago Dermapharm Holding SE repurchases 4,299,190 shares under its public share buyback offer
Published on 03/26/2026 at 19:20, 2 hours 40 minutes ago Critical Path Institute Launches 'One to Millions' to Reshape the Future of Individualized Medicine at Global Scale
Published on 03/26/2026 at 19:09, 2 hours 51 minutes ago 2CRSi SA: Résultats 1er Semestre 2025/26 : Chiffre d'Affaires 204,7 M€ (x9,8) EBITDA de 9,6 M€ (x4,6)
Published on 03/26/2026 at 19:09, 2 hours 51 minutes ago 2CRSi SA: First Half 2025/26 Results: Revenue of €204.7 million (x9.8) EBITDA of €9.6 million (x4.6)
Published on 03/26/2026 at 18:17, 3 hours 43 minutes ago Eiffage se renforce au capital de Getlink et porte sa participation à 29,40 % du capital
Published on 03/26/2026 at 18:17, 3 hours 43 minutes ago Eiffage strengthens its position in Getlink capital
Published on 03/26/2026 at 18:00, 4 hours ago Arrêté des comptes au 31 décembre 2025 et perspectives 2026
